CN105853399A - Application of patchouli alcohol in preparation of medicine for treating chronic gastritis - Google Patents
Application of patchouli alcohol in preparation of medicine for treating chronic gastritis Download PDFInfo
- Publication number
- CN105853399A CN105853399A CN201610026992.4A CN201610026992A CN105853399A CN 105853399 A CN105853399 A CN 105853399A CN 201610026992 A CN201610026992 A CN 201610026992A CN 105853399 A CN105853399 A CN 105853399A
- Authority
- CN
- China
- Prior art keywords
- medicine
- gastritis
- patchouli alcohol
- nitric oxide
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of patchouli alcohol in preparation of a medicine for treating chronic gastritis, and particularly relates to the application of the patchouli alcohol in preparation of the medicine for treating various types of chronic gastritis based on nitric oxide pathways. The medicine is composed of the patchouli alcohol and medicinally acceptable auxiliary materials, wherein each daily used preparation amount contains 1-1000 mg of the patchouli alcohol or 10%-100% of patchouli oil. The patchouli alcohol has the function of treating various types of chronic gastritis, and has the chronic gastritis resisting mechanism related to inhibition of the activity of nitric oxide synthase and production of nitric oxide. Therefore, the patchouli alcohol is expected to become the medicine for treating the various types of chronic gastritis through inhibiting the activity of nitric oxide synthase and production of nitric oxide, and has excellent application prospects in medicine development of chronic gastritis.
Description
Technical field
The invention belongs to pharmaceutical technology field, relate to the patchouli alcohol new application at pharmaceutical technology field.More specifically, relate to
And the application that patchouli alcohol is in the medicine of preparation treatment chronic gastritis.
Background technology
Chronic gastritis means the various chronic gastric mucosa inflammatory lesion that different pathogeny causes, and is a kind of commonly encountered diseases, its morbidity
Rate ranks first in various gastropathy.In clinical manifestation, chronic gastritis lacks specific symptom, the weight of symptom and the disease of gastric mucosa
Range degree is the most non-uniform.Most patient is the most asymptomatic or has indigestion symptom such as upper abdomen dull pain, appetite that degree is different to subtract
Move back, post-prandial fullness, acid regurgitation etc..Chronic Atrophic Gastritis Patients can have anemia, become thin, glossitis, diarrhoea etc., individuals patients accompanies mucosa
Erosion person's upper abdominal pain is more apparent, and can have hemorrhage, such as hematemesis, melena.Symptom usually recurrent exerbation, irregularities stomachache, pain
Often arising in feeding process or after the meal, majority is positioned at epigastrium, umbilicus week, some patients position are not fixed, and the lighter is intermittent
Dull pain or dull pain, severe patient are violent angor.At present, Therapeutic Method mainly eliminates the cause of disease and Drug therapy.(1) disease is eliminated
Cause: dispel the various factor that may cause a disease, as avoided feed to have diet and the medicine of strong stimulation to gastric mucosa, smoking cessation is given up alcohol；Note
Meaning dietetic hygiene, prevents eating and drinking too much at one meal.Active treatment mouth, nose, pharyngeal chronic disease.Strengthen taking exercise and improve body constitution；Should
Mode is preventive, and patient is difficult to adhere to, and curative effect is poor；(2) Drug therapy: can use during panic attacks atropine,
Probanthine, belladonna mixture etc..Gastric hyperacidity can use PPI proton pump inhibitor such as rabeprazole, lansoprazole, omeprazole
Deng, patients whose symptoms were less severe can use H2 receptor blocking agent such as cimetidine, ranitidine, aluminium hydroxide amine etc.；Achlorhydria or anacidity
Person can give 1% dilute hydrochloric acid or Pepsin Mixture, can add with the digestant such as pancreatin tablets, polyzyme tablets with dyspepsia person；Stomach
Mucosa biopsy finds that helicobacter pylori person adds antibiotic therapy；The obvious person of bile reflux can use metoclopramide and motilium to strengthen
Stomach antral peristasis, reduces bile reflux.Hydrotalcite tablet, cholestyramine, sucralfate can be combined with bile acid, mitigation symptoms；But
General effect is not satisfactory, and medication is numerous and diverse, the time is long.
At present, the anti-inflammatory drug used the clinically such as side effect such as glucocorticoid, nonsteroidal antiinflammatory drug is the brightest
Aobvious, and mostly the treatment now for gastritis is to carry out symptomatic treatment for the disease caused by gastritis such as pain, hyperchlorhydria etc.,
There is no and be directed to gastritis and carry out the medicine of etiological treatment.Therefore, research and development have treatment gastritis effect and the medicine of few side effects, tool
There is important realistic meaning.
Patchouli alcohol has another name called patchouli alcohol, Radix seu Caulis Embeliae Parviflorae alcohol, is a kind of tricyclic sesquiterpene compounds, the entitled [1R of its chemistry
(1 α, 4 β, 4A α, 6 β)]-octahydro-4,8A, 9,9-tetramethyl-1,6-methanonaphthalene-1 (2H)-ol, molecular formula is C15H26O, point
Son amount is 222.37, shown in structural formula following structural formula I:
Formula (I)
Its outward appearance is hexagonal trapezohedral tetartohedry crystal, water insoluble, dissolves in ethanol and ether and conventional organic solvent.
The european patent application of Publication No. WO2004110153A1 discloses patchouli alcohol and derivant can be used for pressing down
The asexual propagation of fungus processed and the viscous anti-effect of reduction microorganism, powerful in terms of the cleaning and healing of wound；Publication No.
The Chinese patent application of CN101194899A discloses patchouli alcohol purposes in preparation prevents and treats the medicine of senile dementia；
The Chinese patent application of CN101485647A discloses patchouli alcohol to Influenza A1 virus, Influenza B virus and bird flu
Virus H5N1 has significantly suppression and killing action；The Chinese patent application of CN102920686A discloses patchouli alcohol to Ke
The inhibitory action of Sa Qi virus；The Chinese patent application of CN102895218A discloses patchouli alcohol and makees the suppression of adenovirus
With；The Chinese patent of CN102349884A discloses patchouli alcohol and optionally suppresses helicobacter pylori, does not injures simultaneously
Probiotic bacteria, can keep the ecological balance of human body intestinal canal flora；The Chinese patent application of CN103127038A discloses patchouli alcohol
Purposes in the medicine of preparation treatment bacterial infection disease；The Chinese patent application of CN104306362A discloses hundred autumn Lee
Application in the medicine of alcohol preparation treatment dynamic disorder disease；The Chinese patent application of CN104324018A disclosed for hundred autumns
The application in preparing male sexual disorder medicine or health product of Lee's alcohol.
At present, there are no patchouli alcohol correlational study in terms for the treatment of chronic gastritis and report.
Summary of the invention
The technical problem to be solved in the present invention is to overcome deficiency and the patchouli alcohol application of existing chronic gastritis medicine
Not enough defect, it is provided that patchouli alcohol based on NO pathway in cultured, includes asymptomatic gastritis, chronic in the treatment various inflammation of stomach
Superficial gastritis, chronic atrophic gastritis, gastritis verrucosa, hypertrophic gastritis, chronic erosive gastritis and gastritis are caused
The application of the aspects such as Mucosal atrophy, intestinal epithelial metaplasia, Gastric atypical hyperplasia.
It is an object of the invention to provide patchouli alcohol application in the medicine of preparation treatment chronic gastritis
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
The invention discloses patchouli alcohol new application in the medicine of preparation treatment chronic gastritis.Above-mentioned new application is actually
Patchouli alcohol is based on NO pathway in cultured, the application in terms of the treatment various chronic inflammatory disease of stomach.
Further, said medicine refers to reduce the medicine of stomach content of nitric oxide.
It addition, said medicine refers to suppress the medicine of nitric oxide inducible enzyme gene expression, and one can be suppressed
The medicine of nitrogen oxide inducible enzyme protein expression.
Further, described nitric oxide inducible enzyme refers to eNOS eNOS, inducible nitric oxide
Synthase iNOS and/or neuronal nitric oxide synthase nNOS.
Preferably, above-mentioned chronic gastritis includes asymptomatic gastritis, chronic superficial gastritis, chronic atrophic gastritis, excipuliform
Mucosal atrophy that gastritis, hypertrophic gastritis, chronic erosive gastritis and gastritis are caused, intestinal epithelial metaplasia, stomach is abnormal increases
Raw (Gastric atypical hyperplasia) or gastric cancer etc..
It addition, described chronic gastritis also includes the symptom relevant to chronic gastritis, including halitosis, vomiting, anorexia, belch,
Feel sick, the imbalance of abdominal distention, abdominal discomfort, stomachache, acid regurgitation, dyspepsia, melena, gastrointestinal bacterial flora, neutrophil infiltration, addicted to acid
Property granulocyte infiltration, lymph follicle.
A kind of by patchouli alcohol with the medicine for the treatment of chronic gastritis that forms of medically acceptable adjuvant, also in the present invention
Protection domain within.
Preferably, containing patchouli alcohol 1～1000mg in the every daily amount of formulation of described medicine.
It is highly preferred that containing patchouli alcohol 10～1000mg in the every daily amount of formulation of described medicine.
It addition, the dosage form of said medicine can be any dosage form medically approved.
Preferably, the dosage form of described medicine can be common oral formulations, such as tablet, capsule, drop pill, granule, mouth
Take solution, outstanding mixture, stomach suspending agent or gastric retentive oral dosage etc..
Further, since the chemical constitution of patchouli alcohol is complicated, synthesis technique is superfluous long and complex, therefore its main source current
In hundred autumn Lee oil, above-mentioned patchouli alcohol also can replace with hundred autumn Lee's oil.Hundred autumn Lee's oil are that Labiatae stings stamen grass platymiscium hundred autumn
The volatile oil of Lee, it has promotion gastric secretion, strengthens digestive function, spasmolytic, anti-dermatophyte and the effect of tinea bacterium.System at present
The main production of standby patchouli alcohol is first to extract hundred autumn Lee oil from hundred autumn Lee, then isolates hundred autumn Lee from hundred autumn Lee's oil
Alcohol, concrete separation method can refer to the method disclosed in the patent of Publication No. CN101691323 B to be implemented.According to publication number
The intermediate product that CN101691323 B patent system is oily for producing hundred autumn Lee during patchouli alcohol, hundred in these products
Autumn Lee's alcohol content may be up to more than 70%, has the drug activity identical with patchouli alcohol.
The medicine of the most above-mentioned treatment chronic gastritis by hundred autumn Lee oil containing patchouli alcohol and medically can also connect
The adjuvant being subject to forms, and in the most every daily amount of formulation, the content of hundred autumn Lee oil is 10%～100%.
Chronic gastritis is one of common disease of stomach, because gastric cancer is had certain induction to make by chronic gastritis
With, therefore regarded as disease or precancerous condition before gastric cancer by WHO.The pests occurrence rule of gastric cancer is the most universally acknowledged, from normally
Gastric mucosa develops into chronic gastritis, chronic atrophic gastritis, intestinal epithelial metaplasia, gastrointestinal paraplasm, is finally developed to gastric cancer.Right
The treatment in time of chronic gastritis can effectively suppress the development of the course of disease.Nitric oxide (Nitric Oxide, NO) is to be urged by NOS
Generate after changing arginine.Under normal physiological condition, NO is mainly closed by eNOS and nervous system type nitric oxide
Enzyme induction produces, and is mainly used in regulating and controlling stomach blood flow and mucus amount, plays the effect of protection stomach.And under pathological state, lure
Conductivity type nitricoxide synthase produces in a large number, and then creates the NO of excess, and the NO that now excess generates can directly cause cell toxicant
Act on or by generating the bigger peroxide nitro anion of toxicity and hydroxy radical with oxygen-derived free radicals oxidation, thus aggravate inflammation
Reaction.The present invention studies discovery, and patchouli alcohol has the effect of extremely strong suppression nitricoxide synthase, by suppression nitric oxide
Synthase activity, thus suppress the generation of NO can play the effect for the treatment of gastritis, therefore, patchouli alcohol has treatment a variety of causes
Cause the ability of chronic gastritis.
The method have the advantages that
The invention provides a kind of new application at pharmaceutical technology field of patchouli alcohol, i.e. in treating various chronic gastritiss
Application.Described patchouli alcohol has the effect of various chronic gastritis, the mechanism of its resisting chronic gastritis and suppression nitricoxide synthase
Activity and nitric oxide produce relevant.Therefore, patchouli alcohol is expected to become by suppression nitric oxide synthase activity and an oxidation
Nitrogen produces, thus plays the medicine treating various chronic gastritis effects, has excellence in terms of the drug development of chronic gastritis
Application prospect.
Accompanying drawing explanation
Fig. 1 is the patchouli alcohol impact on stomach Enos, Nnos, Inos gene expression.
Fig. 2 is the patchouli alcohol impact on stomach Enos, Nnos, Inos protein expression.
Fig. 3 is the patchouli alcohol impact on stomach content of nitric oxide.
Detailed description of the invention
Further illustrate the present invention below in conjunction with Figure of description and specific embodiment, but embodiment is not to the present invention
Limit in any form.Unless stated otherwise, the present invention uses reagent, method and apparatus are the examination of the art routine
Agent, method and apparatus.
Unless stated otherwise, agents useful for same of the present invention and material are commercial.
The impact on nitric oxide inducible enzyme gene expression of embodiment 1 patchouli alcohol
1, material and method
(1) material
Chloroform (Guangzhou reagent head factory)；Isopropanol (Guangzhou reagent head factory)；DEPC(Sigma)；Super Real Pre Mix×
Plus(SYBR Green) (TIANGEN BIOTECH CO., LTD)；Trizol(Takara)；Fast Quant RT Kit
(With gDNase) (TIANGEN BIOTECH(BEIJING)CO.,LTD)；Electric homogenizer (TIANGEN BIOTECH
CO., LTD)；Refrigerated centrifuger (Eppendorff).
(2) medicine
Patchouli alcohol (HPLC > 98%) uses poloxamer188 compounding pharmaceutical.According to medicine: poloxamer188=1:5 ratio mixing
After, 70 DEG C of water-baths melt, and magnetic agitation is sufficiently mixed medicine, after-20 DEG C are placed 24 hours, use distilled water to be configured to required dense
Degree.
(3) method
1) 24 SD rats, male and female half and half, 250～300g, it is randomly divided into matched group, patchouli alcohol basic, normal, high dosage group, often
Organize 6.Blank group gavage poloxamer, administration group according to 0.1mg/kg, 1 mg/kg, 10 mg/kg dosage gavage patchouli alcohols,
Totally 7 days.Last be administered after 1h, put to death rat, take after stomach tissue uses normal saline flushing clean, take 100mg and put into 1ml
In TRIZOL.Method extracts RNA to specifications, uses Q-PCR method detection eNOS after reverse transcription
(eNOS), the change that neuronal nitric oxide synthase (nNOS) is expressed.
2) 24 SD rats, male and female half and half, 250～300g, it is randomly divided into matched group, the basic, normal, high dosage of patchouli alcohol
Group, often group 6.Blank group gavage poloxamer, administration group according to 0.1mg/kg, 1 mg/kg, 10 mg/kg dosage gavage hundred autumns
Lee's alcohol, totally 7 days.1h, gavage dehydrated alcohol 1ml after last administration, put to death rat after 1h, take stomach tissue and use normal saline punching
After wash clean, take 100mg and put in 1ml TRIZOL.Method extracts RNA to specifications, uses the inspection of Q-PCR method after reverse transcription
Survey the expression change of nitric oxide synthase type (iNOS).Primer sequence is shown in Table 1, and amplification system is shown in Table 2, and amplification condition is shown in Table
3。
Table 1 primer sequence
Table 2 amplification system
Table 3 amplification condition
2, result
As shown in Figure 1, patchouli alcohol can reduce normal rat stomach Enos with significance at 0.1mg/kg and 1mg/kg to result
Gene expression；Patchouli alcohol can reduce ethanol inflammatory model rat stomach Inos with significance at 0.1mg/kg and 10mg/kg
Gene expression.
The impact on nitric oxide inducible enzyme protein expression of embodiment 2 patchouli alcohol
1, material and method
(1) material
Histone lysate (the green skies)；The green skies of PMSF()；Pvdf membrane (Milipore)；Protein Marker
(Thermo)；Refrigerated centrifuger (Eppendorff)；Vertial electrophorestic tank, power supply (6 1).
(2) medicine
Patchouli alcohol (HPLC > 98%) uses poloxamer188 compounding pharmaceutical.According to medicine: poloxamer188=1:5 ratio mixing
After, 70 DEG C of water-baths melt, and magnetic agitation is sufficiently mixed medicine, after-20 DEG C are placed 24 hours, use distilled water to be configured to required dense
Degree.
(3) method
1) 24 SD rats, male and female half and half, 250～300g, it is randomly divided into matched group, patchouli alcohol basic, normal, high dosage group, often
Organize 6.Blank group gavage poloxamer, administration group according to 0.1mg/kg, 1 mg/kg, 10 mg/kg dosage gavage patchouli alcohols,
Totally 7 days.Last be administered after 1h, put to death rat, take after stomach tissue uses normal saline flushing clean, take 100mg and put into tissue
In lysate, total protein, Western Blot method detection eNOS (eNOS), nervous system type one oxygen are extracted in homogenate
Change the change that nitrogen synthase (nNOS) is expressed.
For concrete grammar, the total protein of extraction adds appropriate normal saline dilution and makes last total protein applied sample amount
It is 100 μ g, uses 7.5% polyacrylamide gel electrophoresis, 30min 80v electrophoresis horizontalization row, rear use 90min 120v electrophoresis.
90min 200mA crossing current transferring film is put on pvdf membrane, and 5% defatted milk powder (containing 0.05% tween) closes 1 hour, and TBST washes film 3 times,
5min every time.Corresponding one is used to resist 4 DEG C to hatch (eNOS and nNOS is 1:500 and uses defatted milk powder dilution) overnight.Second
After it washes film, use two anti-(1:1000) incubated at room 2 hours.After washing film, ECL exposure record data.
2) 24 SD rats, male and female half and half, 250～300g, it is randomly divided into matched group, the basic, normal, high dosage of patchouli alcohol
Group, often group 6.Blank group gavage poloxamer, administration group according to 0.1mg/kg, 1 mg/kg, 10 mg/kg dosage gavage hundred autumns
Lee's alcohol, totally 7 days.1h, gavage dehydrated alcohol 1ml after last administration, put to death rat after 1h, take stomach tissue and use normal saline punching
After wash clean, taking 100mg and put in Tissue lysates, total protein, Western Blot method detection induction type one oxygen are extracted in homogenate
Change the expression change of nitrogen synthase (iNOS).
For concrete grammar, the total protein of extraction adds appropriate normal saline dilution and makes last total protein applied sample amount
It is 40 μ g, uses 8% polyacrylamide gel electrophoresis, 30min 80v electrophoresis horizontalization row, rear use 90min 120v electrophoresis.
90min 350mA crossing current transferring film is put on pvdf membrane, and 5% defatted milk powder (containing 0.05% tween) closes 1 hour, and TBST washes film 3 times,
10min every time.Corresponding one is used to resist 4 DEG C to hatch (iNOS is that 1:200 uses defatted milk powder dilution) overnight.Within second day, wash film
After, use two anti-(1:5000) incubated at room 1 hour.After washing film, ECL exposure record data.
2, result
As shown in Figure 2, patchouli alcohol can reduce normal rat with significance at 0.1mg/kg, 1mg/kg and 10mg/kg to result
The protein expression of stomach Enos；Patchouli alcohol can reduce ethanol inflammatory model rat stomach Inos's with significance at 10mg/kg
Protein expression.
The impact on stomach content of nitric oxide of embodiment 3 patchouli alcohol
1, materials and methods
(1) material
Nitric oxide test kit (the green skies)；The green skies of PMSF()；Histone extracting solution (the green skies)；BCA albumen is fixed
Amount test kit (the green skies)；Refrigerated centrifuger (Eppendorff)；Microplate reader (Thermo).
(2) medicine
Patchouli alcohol (HPLC > 98%) uses poloxamer188 compounding pharmaceutical.According to medicine: poloxamer188=1:5 ratio mixing
After, 70 DEG C of water-baths melt, and magnetic agitation is sufficiently mixed medicine, after-20 DEG C are placed 24 hours, use distilled water to be configured to required dense
Degree.
(3) method
24 SD rats, male and female half and half, 250-300g, it is randomly divided into matched group, patchouli alcohol basic, normal, high dosage group, often organize 6
Only.Blank group gavage poloxamer, administration group according to 10mg/kg, 20 mg/kg, 40 mg/kg dosage gavage patchouli alcohols, totally 7
My god.Last be administered after 1h, put to death rat, take after stomach tissue uses normal saline flushing clean, take 100mg and put into Tissue Lysis
In liquid, total protein is extracted in homogenate, and BCA method measures extracting solution protein concentration, and RNA isolation kit measures NO content in extracting solution.
2, result:
As shown in Figure 3, patchouli alcohol is at 10mg/kg, and 20 mg/kg and 40 mg/kg can reduce normal big with significance for result
The content of Mus stomach NO.
Embodiment 4 tablet
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as tablet.Oral, the most daily
The mg Han patchouli alcohol 1～1000 in amount of formulation.For treating chronic superficial gastritis.
Embodiment 5 tablet
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as tablet, and patchouli alcohol content is
0.1～100 mg/ sheets.Oral, every day 1～3 times, each 1～3.For treating chronic atrophic gastritis.
Embodiment 6 capsule
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as capsule.Oral, the most daily
The mg Han patchouli alcohol 0.1～1000 in amount of formulation.For treating chronic atrophic gastritis.
Embodiment 7 capsule
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as capsule, and patchouli alcohol content is
0.1～100 mg/ grains.Oral, every day 1～3 times, each 1～3.For treating chronic superficial gastritis.
Embodiment 8 drop pill
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as drop pill.Oral, the most daily
The mg Han patchouli alcohol 0.1～1000 in amount of formulation.For treating chronic atrophic gastritis.
Embodiment 9 drop pill
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as drop pill, and patchouli alcohol content is
0.1～100 mg/ grains.Oral, every day 1～3 times, each 1～3.For treating chronic superficial gastritis.
Embodiment 10 granule
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as granule.Oral, wherein every day
With the mg Han patchouli alcohol 0.1～1000 in amount of formulation.For treating Mucosal atrophy, the enteric epithelium that chronic gastritis is caused
Life, Gastric atypical hyperplasia etc..
Embodiment 11 granule
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as granule, and patchouli alcohol content is
0.1～100 mg/ bags.Oral, every day 1～3 times, each 1～3 bag.For treating chronic superficial gastritis.
Embodiment 12 oral solution
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as oral solution.Oral, wherein
The mg Han patchouli alcohol 0.1～1000 in every daily amount of formulation.For treating chronic erosive gastritis.
Embodiment 13 oral solution
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as oral solution, and patchouli alcohol contains
Amount is 0.1～100 mg/ bottles.Oral, every day 1～3 times, each 1～3 bottle.For treating chronic superficial gastritis.
Embodiment 14 stomach suspending agent, gastric retentive oral dosage
Taking patchouli alcohol is crude drug, adds medically acceptable adjuvant composition, is prepared as stomach suspending agent, gastric retentive oral dosage.Mouthful
Clothes, the mg Han patchouli alcohol 0.1～1000 in the most every daily amount of formulation.For treating chronic erosive gastritis.
Claims (10)
1. patchouli alcohol or the application in the medicine of preparation treatment chronic gastritis of hundred autumn Lee oil.
Apply the most according to claim 1, it is characterised in that described medicine refers to reduce stomach content of nitric oxide
Medicine.
Apply the most according to claim 1, it is characterised in that described medicine refers to suppress nitric oxide inducible enzyme gene
The medicine expressed.
Apply the most according to claim 1, it is characterised in that described medicine refers to suppress nitric oxide inducible enzyme albumen
The medicine expressed.
5. apply according to described in claim 3 or 4, it is characterised in that described nitric oxide inducible enzyme refers to endothelium in type one oxidation
Nitrogen synthase eNOS, nitric oxide synthase type iNOS and/or neuronal nitric oxide synthase nNOS.
Apply the most according to claim 1, it is characterised in that described chronic gastritis includes asymptomatic gastritis, chronic superficial
The gastric mucosa that gastritis, chronic atrophic gastritis, gastritis verrucosa, hypertrophic gastritis, chronic erosive gastritis, gastritis are caused withers
Contracting, intestinal epithelial metaplasia, stomach paraplasm or gastric cancer.
Apply the most according to claim 1, it is characterised in that described chronic gastritis also includes the disease relevant to chronic gastritis
Shape, including halitosis, vomiting, anorexia, belch, nauseating, abdominal distention, abdominal discomfort, stomachache, acid regurgitation, dyspepsia, melena, gastrointestinal tract
Dysbacteriosis, neutrophil infiltration, eosinophils, lymph follicle.
8. the medicine treating chronic gastritis, it is characterised in that described medicine by patchouli alcohol or hundred autumn Lee oil and medically
Acceptable adjuvant forms.
Medicine the most according to claim 8, it is characterised in that in the every daily amount of formulation of described medicine containing patchouli alcohol 1～
1000mg or hundred autumn Lee oil 10%～100%.
Medicine the most according to claim 8, it is characterised in that the dosage form of described medicine can be tablet, capsule, drop pill,
Granule, oral solution, outstanding mixture, stomach suspending agent or gastric retentive oral dosage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610026992.4A CN105853399B (en) | 2016-01-15 | 2016-01-15 | Application of the patchouli alcohol in the drug for preparing treatment chronic gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610026992.4A CN105853399B (en) | 2016-01-15 | 2016-01-15 | Application of the patchouli alcohol in the drug for preparing treatment chronic gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105853399A true CN105853399A (en) | 2016-08-17 |
| CN105853399B CN105853399B (en) | 2018-10-12 |
Family
ID=56623861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610026992.4A Active CN105853399B (en) | 2016-01-15 | 2016-01-15 | Application of the patchouli alcohol in the drug for preparing treatment chronic gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853399B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114903878A (en) * | 2022-04-22 | 2022-08-16 | 广州医科大学 | Application of sesquiterpenoids in inhibiting activity of TRPA1 channel |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349884A (en) * | 2011-08-26 | 2012-02-15 | 东莞广州中医药大学中医药数理工程研究院 | Application of patchouli alcohol in preparation of helicobacter pylori resistant medicament |
-
2016
- 2016-01-15 CN CN201610026992.4A patent/CN105853399B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102349884A (en) * | 2011-08-26 | 2012-02-15 | 东莞广州中医药大学中医药数理工程研究院 | Application of patchouli alcohol in preparation of helicobacter pylori resistant medicament |
Non-Patent Citations (2)
| Title |
|---|
| TOYOKO GOTO ET AL.: "Enhanced Expression of Inducible Nitric Oxide Synthase and Nitrotyrosine in Gastric Mucosa of Gastric Cancer Patients.", 《CLINICAL CANCER RESEARCH》 * |
| YAN-FANGXIAN ET AL.: "Anti-inflammatory effect of patchouli alcohol isolated from Pogostemonis Herba in LPS-stimulated RAW264.7 macrophages", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114903878A (en) * | 2022-04-22 | 2022-08-16 | 广州医科大学 | Application of sesquiterpenoids in inhibiting activity of TRPA1 channel |
| CN114903878B (en) * | 2022-04-22 | 2023-09-22 | 广州医科大学 | Application of sesquiterpenoids in inhibiting activity of TRPA1 channel |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105853399B (en) | 2018-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016062274A1 (en) | Applications of digestive disease medicament in preparing cancer-inhibiting pharmaceutical composition | |
| US20050222258A1 (en) | Pharmaceuticals comprising shikonins as active constituent | |
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| CN105853399A (en) | Application of patchouli alcohol in preparation of medicine for treating chronic gastritis | |
| CN111265599A (en) | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis | |
| JP2007505151A (en) | Application of bamboo leaf flavone in preventive and therapeutic drugs for prostate diseases and health foods | |
| CN1994352B (en) | Use of total glucosides extract of cocklebur fruit in preparation of product for resisting inflammatory reaction | |
| TWI239244B (en) | Method for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract | |
| CN1911260A (en) | Application of phenolic acids active components from dandelion for inhibiting gynecologic pelvic inflammatory disease | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN105853653B (en) | Pharmaceutical composition for treating chronic gastritis and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| WO2020187019A1 (en) | Traditional chinese medicine laxative composition for treating constipation, preparation method therefor and application thereof | |
| CN110433271A (en) | A kind of pharmaceutical composition and its preparation method and application for treating functional dyspepsia FD | |
| CN113425713B (en) | Pharmaceutical composition for treating duodenal ulcer | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| WO2014047780A1 (en) | Pharmaceutical composition containing apigenin and apigenin derivative and oridonin and oridonin derivative and use thereof | |
| RU2545687C1 (en) | Method for helicobacter pylori eradication of gastroduodenal zone | |
| TWI639430B (en) | Use of pharmaceutical composition for manufacturing drug of treating gastric cancer | |
| CN107307214A (en) | A kind of feed addictive for treating diarrhea of pigs | |
| CN102076346A (en) | Pharmaceutical compositions for human and preparation of bismuth or zinc agent | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN101637527A (en) | Application method of amur cork for preparing digestive ulcer medicament | |
| Jentschura | Thyroid Disease and Taurine Consumption: A Case Study on Enzyme-Supported Immunotherapy | |
| Zhao et al. | Inhibitory Effect of Semen Litchi Drug Serum on the Proliferation of Human Hepatoma HepG2 Cells and Expression of VEGF and MMP-9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |